**Author details**

Wenyong Tan\*, Xianming Li and Yong Dai

\*Address all correspondence to: tanwyym@hotmail.com

Department of Oncology, The Second Clinical Medical College (Shenzhen People's Hospital), Ji'nan University, Shenzhen, China

### **References**


[16] Tan W, Wang X, Qiu D, et al. Dosimetric comparison of intensity-modulated radiotherapy plans, with or without anterior myocardial territory and left ventricle as organs at risk, in early-stage left-sided breast cancer patients. *International Journal of Radiation Oncology Biology Physics*. Dec 1 2011;81(5):1544–1551.

[4] Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the

[5] Group EBCTC. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer

[6] Group EBCTC. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data

[7] Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised

[8] Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. *Journal of Clinical* 

[9] Rodrigues G, Choy H, Bradley J, et al. Definitive radiation therapy in locally advanced non-small cell lung cancer: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. *Practical Radiation* 

[10] Shapiro J, van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. *The Lancet Oncology*. Sep 2015;16(9):1090–1098.

[11] Rustgi AK, El-Serag HB. Esophageal carcinoma. *The New England Journal of Medicine*. Dec

[12] Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. *International Journal of Radiation Oncology Biology Physics*. Mar 1

[13] Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *The New England Journal of Medicine*. Mar 14

[14] Tan W, Wu X, Wei S. Chemoradiotherapy-associated cardiovascular toxicity: a need of cardio-oncology to improve. *Journal of Clinical & Experimental Cardiology*. J Clin Exp

[15] Bezjak A, Temin S, Franklin G, et al. Definitive and adjuvant radiotherapy in locally advanced non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. *Journal of Clinical Oncology*. Jun 20

for 8135 women in 22 randomised trials. *The Lancet*. 2014;383(9935):2127–2135.

randomised trials. *Lancet*. May 14–20 2005;365(9472):1687–1717.

controlled trial. *Lancet*. Aug 1 2009;374(9687):379–386.

*Oncology*. May 1 2010;28(13):2181–2190.

*Oncology*. May-Jun 2015;5(3):141–148.

25 2014;371(26):2499–2509.

2010;76(3):656–665.

204 Radiotherapy

2013;368(11):987–998.

2015;33(18):2100–2105.

Cardiolog 5:320.

Trialists' Collaborative Group. *Lancet*. May 20 2000;355(9217):1757–1770.


[41] De Puysseleyr A, Mulliez T, Gulyban A, et al. Improved cone-beam computed tomography in supine and prone breast radiotherapy. Surface reconstruction, radiation exposure, and clinical workflow. *Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft … [et al]*. Nov 2013;189(11):945–950.

[29] Marks LB, Yu X, Prosnitz RG, et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. *International Journal of Radiation Oncology Biology* 

[30] Prosnitz RG, Hubbs JL, Evans ES, et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treat-

[31] Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? *International Journal of Radiation* 

[32] Lee MS, Finch W, Mahmud E. Cardiovascular complications of radiotherapy. *The* 

[33] Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. *International Journal of Radiation Oncology Biology Physics*. Mar 1 2010;76(3 Suppl):S77–85.

[34] Feng M, Moran JM, Koelling T, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. *International* 

[35] Das SK, Baydush AH, Zhou S, et al. Predicting radiotherapy-induced cardiac perfusion

[36] Shah C, Badiyan S, Berry S, et al. Cardiac dose sparing and avoidance techniques in breast cancer radiotherapy. *Radiotherapy and Oncology: Journal of the European Society for* 

[37] Korreman SS, Pedersen AN, Aarup LR, Nottrup TJ, Specht L, Nystrom H. Reduction of cardiac and pulmonary complication probabilities after breathing adapted radiotherapy for breast cancer. *International Journal of Radiation Oncology Biology Physics*. Aug 1

[38] Lymberis SC, deWyngaert JK, Parhar P, et al. Prospective assessment of optimal individual position (prone versus supine) for breast radiotherapy: volumetric and dosimetric correlations in 100 patients. *International Journal of Radiation Oncology Biology Physics*.

[39] Fernandez-Lizarbe E, Montero A, Polo A, et al. Pilot study of feasibility and dosimetric comparison of prone versus supine breast radiotherapy. *Clinical & Translational* 

[40] Jozsef G, DeWyngaert JK, Becker SJ, Lymberis S, Formenti SC. Prospective study of cone-beam computed tomography image-guided radiotherapy for prone accelerated partial breast irradiation. *International Journal of Radiation Oncology Biology Physics*. Oct 1

*Physics*. Sep 1 2005;63(1):214–223.

206 Radiotherapy

ment. *Cancer*. Oct 15 2007;110(8):1840–1850.

*Oncology Biology Physics*. Jan 1 2007;67(1):10–18.

defects. *Medical Physics*. Jan 2005;32(1):19–27.

2006;65(5):1375–1380.

Nov 15 2012;84(4):902–909.

2011;81(2):568–574.

*Oncology*. Jun 2013;15(6):450–459.

*Therapeutic Radiology and Oncology*. 2014;112:9–16.

*American Journal of cardiology*. Nov 15 2013;112(10):1688–1696.

*Journal of Radiation Oncology Biology Physics*. Jan 1 2011;79(1):10–18.


[65] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*. Oct 15 2013;62(16):e147–239.

[52] Jimenez RB, Goma C, Nyamwanda J, et al. Intensity modulated proton therapy for postmastectomy radiation of bilateral implant reconstructed breasts: a treatment planning study. *Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology* 

[53] Ng AK, Li S, Neuberg D, et al. Long-term results of a prospective trial of mantle irradiation alone for early-stage Hodgkin's disease. *Annals of Oncology*. Nov 2006;17(11):1693–1697.

[54] Page V, Gardner A, Karzmark CJ. Physical and dosimetric aspects of the radiotherapy of malignant lymphomas. I. The mantle technique. *Radiology*. Sep 1970;96(3):609–618. [55] Anderson H, Deakin DP, Wagstaff J, et al. A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: a report from the Manchester lymphoma group. *British Journal of Cancer*. Jun 1984;49(6):695–702.

[56] Specht L, Yahalom J, Illidge T, et al. Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG). *International Journal of Radiation Oncology Biology Physics*. Jun 18 2013.

[57] Ansell SM. Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clinic proceedings

[58] Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. *The Lancet Oncology*.

[59] Chang JY, Jabbour SK, De Ruysscher D, et al. Consensus statement on proton therapy in early-stage and locally advanced non-small cell lung cancer. *International Journal of* 

[60] Tajstra M, Gadula-Gacek E, Buchta P, Blamek S, Gasior M, Kosiuk J. Effect of therapeutic ionizing radiation on implantable electronic devices: systematic review and practical

[61] Salerno F, Gomellini S, Caruso C, et al. Management of radiation therapy patients with cardiac defibrillator or pacemaker. *La Radiologia Medica*. Jun 2016;121(6):515–520.

[62] Shu J, Zhou J, Patel C, Yan GX. Pharmacotherapy of cardiac arrhythmias—basic science for clinicians. *Pacing and Clinical Electrophysiology: PACE*. Nov 2009;32(11):1454–1465. [63] Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. *CA: A Cancer Journal for Clinicians*. Jul

[64] Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. *Annals of* 

*Radiation Oncology Biology Physics*. May 1 2016;95(1):505–516.

guidance. *Journal of Cardiovascular Electrophysiology*. 2016;27:1247–51.

*and Oncology*. May 2013;107(2):213–217.

2015;90:1574–83.

208 Radiotherapy

2015;16(2):187–199.

2016;66(4):309–325.

*Oncology*. Oct 2012;23 Suppl 7:vii155–166.

